ArticleJournal of inflammation research2025
Association of Systemic Inflammatory Response Index with Disease Severity and Adverse Outcome in Chronic Thromboembolic Pulmonary Hypertension.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The predictive value of the systemic immune-inflammation index in chronic thromboembolic pulmonary hypertension.Medicine · 2026Article
- Deep Vein Thrombosis Prevention in Acute Ischemic Stroke Patients with Lower Limb Paralysis: A Narrative Review.Journal of clinical medicine · 2026Review
- Dysregulated lipid metabolites GML and GMO were associated with cytotoxic T cell function and serve as biomarkers for acute pulmonary embolism.Frontiers in immunology · 2026Article
- Effects of balloon pulmonary angioplasty on cardiac and pulmonary functions and complications in patients with chronic thromboembolic pulmonary hypertension.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Composite inflammatory markers, such as the systemic inflammatory response index (SIRI), are associated with the severity and progression of several cardiovascular diseases. However, the relationship between SIRI and chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. We hypothesized that elevated SIRI levels would correlate with disease severity and independently predict adverse clinical outcomes in patients with CTEPH. This study aimed to clarify the predictive value of SIRI in patients with CTEPH. Methods: This retrospective cohort study included 383 patients with CTEPH treated at Fuwai Hospital between June 2013 and June 2021. Receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic performance of SIRI to other inflammatory indices and identify the optimal cutoff value. Kaplan-Meier analysis and Cox proportional hazard models were used to examine the relationship between SIRI and clinical worsening. Results: During a mean follow-up period of 30.6 months, 79 participants experienced clinical worsening. The SIRI was significantly correlated with established markers of CTEPH severity, including the 6-minute walk distance, N-terminal pro-brain natriuretic peptide, and hemodynamic parameters. Kaplan-Meier curve revealed that individuals with a SIRI ≥ 0.80 exhibited significantly poorer survival rates and a shorter time to clinical worsening compared to those with a SIRI < 0.80 (P < 0.01). Adjusted Cox proportional hazards analysis revealed that SIRI remained an independent predictor of clinical worsening (hazard ratio (HR) 2.033; 95% confidence interval (CI) 1.227-3.370). ROC analysis revealed that SIRI exhibited the highest area under the curve value of 0.730 (95% CI 0.659-0.810). Incorporating SIRI into The COMPERA 2.0, the risk score improved its predictive value for adverse outcomes in patients with CTEPH. Conclusion: SIRI is a valuable prognostic marker for CTEPH, correlating with established markers of disease severity and independently predicting clinical worsening. SIRI provides additional prognostic predictive value when used in conjunction with the risk score of COMPERA 2.0.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.